Retatrutide · TRIUMPH-Outcomes
This is the long-term cardiovascular/renal outcome trial, not TRIUMPH-1/2/3 weight-loss readouts already reported. No near-term result date is asserted. retatrutide — phase 3 study in Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD). NCT06383390 lists Time to First Occurrence of Composite Endpoints as a primary outcome (Randomization up to Study Completion (Approximate 248 Weeks)). Registry status: active not recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2029-02 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Long-horizon study — result date not confirmed
Potential outcome market
Will retatrutide meet the prespecified primary endpoint in NCT06383390 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.